Non-alcoholic fatty liver disease has been reframed in recent years as metabolic dysfunction–associated steatotic liver disease (MASLD) to emphasize its origin in cardio-metabolic dysregulation1. MASLD affects approximately 25% of the global population, with an even higher prevalence rate of 27% in Asia2. Importantly, MASLD is not just a liver problem—it represents a manifestation of the broader metabolic syndrome and carries significant cardiometabolic consequences3. At a recent symposium, Dr. Sollano reviewed the evolving therapeutic landscape in his lecture and highlighted the role of essential phospholipids (EPLs)— especially phosphatidylcholine—as a useful liver-supportive agent in real-world MASLD management, particularly where access to newer treatments remains constrained.

Despite the typically indolent nature of marginal zone lymphoma (MZL), treatment options for patients with relapsed or refractory (R/R) disease have long been limited and largely extrapolated from broader indolent
non-Hodgkin lymphoma studies. Conventional chemoimmunotherapy, though effective, can be poorly tolerated in older or comorbid patients, while first-generation Bruton tyrosine kinase (BTK) inhibitors like ibrutinib have been associated with off-target toxicities. This created a critical therapeutic gap for patients requiring prolonged treatment with manageable safety profiles. Zanubrutinib, a next-generation BTK inhibitor engineered for greater target selectivity and improved tolerability, has emerged as a promising solution. At a recent symposium, Dr. Chandramouli Nagarajan presented the findings of the MAGNOLIA trial, a pivotal phase II study that evaluated Zanubrutinib as monotherapy in patients with R/R MZL. By focusing on a real-world population, including elderly patients, the study offers compelling evidence for the role of Zanubrutinib in reshaping the treatment landscape of MZL.

At a recent webinar, Professor Dan Siskind, Professor of Psychiatry at the University of Queensland, Brisbane, Australia, presented key recommendations from the International College of Neuropsychopharmacology (CINP)-endorsed International Guidelines for the Algorithmic Treatment of Schizophrenia (INTEGRATE).

Since the publication of the 2019 European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidemia, various landmark clinical trials regarding therapies for dyslipidemia have been publ...

Follicular lymphoma (FL) is an indolent form of non-Hodgkin’s lymphoma (NHL) that originates from germinal centre B cells 1 and is the second most common NHL subtype worldwide. Although first-line treatment achieves a complete response (CR) an...

Hodgkin’s lymphoma (HL) is a rare monoclonal lymphoid neoplasm that consists of two subtypes: classical HL (cHL- 95% cases) and nodular lymphocyte predominant HL (NLP-HL) 1,2 . Notably, cHL has a bimodal age distribution that initially peaks a...

Chronic Hepatitis B (CHB) remains a substantial public health burden in Hong Kong, with recent data indicating approximately 5.6% of the local population living with the infection, affecting over 410,000 individuals 1 . While antiviral therapies hav...

CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are of the same disease. But, in CLL cancer cells are mostly found in the blood and bone marrow; while in SLL cancer cells are mostly found in the lymph nodes. CLL/SLL belongs t...

Statins are the front-line therapeutic agents for preventing cardiovascular diseases (CVD) and atherosclerotic disorders related to hypercholesterolemia by lowering low-density lipoprotein cholesterol (LDL-C) levels 1 . In addition to this primary i...

The disease burden of mental disorders has become increasingly relevant as this causes a high degree of individual and social suffering, whereas mood and anxiety disorders are commonly involved. Previous pooled analysis suggested that the lifetime p...

Hodgkin lymphoma (HL) is a rare B-cell lymphatic malignancy distinguished by its unique histological, immunophenotypic, and clinical characteristics 1,2 . According to the 2022 Hong Kong Cancer Registry data, HL accounts for ~3% of all haematologica...

Hyperphosphataemia is a hallmark of chronic kidney disease–mineral and bone disorder (CKD-MBD), contributing significantly to vascular calcification, cardiovascular morbidity, and mortality in dialysis patients 1-2 . Effective management of el...